Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Neurodegenerative diseases

New biomarker improves diagnosis of Parkinson's and LBD

A biomarker discovered in the cerebrospinal fluid could improve diagnosis of Parkinson's disease and dementia with Lewy bodies.

News • Affordable diagnostics

Detecting bacterial infection with simple breath test

Bacterial infections can be difficult to distinguish from viral infections and inflammation, but a simple breath test may change that. This could reduce unnecessary antibiotic prescriptions.

News • pTau217 and BDTau

Siemens Healthineers expands brain health research portfolio with new biomarker assays

Siemens Healthineers has announced the availability of two blood-based biomarker tests for research use: the Atellica IM Phosphorylated tau 217 (pTau217) and the Atellica IM Brain Derived Tau (BDTau)…

Related articles